SAB Biotherapeutics (SABS) EBIT (2021 - 2026)
SAB Biotherapeutics (SABS) reported EBIT of -$20.0 million for Q1 2026, down 85.64% on a YoY basis from -$139.3 million in Q1 2025, and down 26.81% quarter-over-quarter from -$15.8 million in Q4 2025.
SAB Biotherapeutics (SABS) EBIT (2021 - 2026) Analysis & Trends
SAB Biotherapeutics has reported EBIT for 6 years, with the latest figure at -$20.0 million in Q1 2026.
- For the quarter ending Q1 2026, EBIT fell 85.64% year-over-year to -$20.0 million; the trailing twelve-month figure through Mar 2026 stood at -$58.2 million (down 37.56% YoY), and the FY2025 full-year result was -$49.0 million, down 14.08% from the prior year.
- EBIT for Q1 2026 stood at -$20.0 million, down from -$15.8 million in the prior quarter.
- The five-year high for EBIT was $17.1 million in Q4 2022, with the low at -$20.0 million in Q1 2026.
- Historically, EBIT has averaged -$9.1 million across 5 years, with a median of -$10.0 million in 2024.
- The largest YoY upside for EBIT was 333.21% in 2022 against a maximum downside of 924.07% in 2022.
- SAB Biotherapeutics' EBIT stood at $17.1 million in 2022, then plunged by 210.2% to -$18.9 million in 2023, then soared by 46.97% to -$10.0 million in 2024, then tumbled by 57.56% to -$15.8 million in 2025, then slipped by 26.81% to -$20.0 million in 2026.
- The last three EBIT figures came in at -$20.0 million (Q1 2026), -$15.8 million (Q4 2025), and -$12.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.76 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.51 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | SAB Biotherapeutics | 214.77 Mn | 214.77 Mn | - | -20.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.00 Mn |
| Dec 31, 2025 | -15.77 Mn |
| Sep 30, 2025 | -12.68 Mn |
| Jun 30, 2025 | -9.73 Mn |
| Mar 31, 2025 | -10.77 Mn |
| Dec 31, 2024 | -10.01 Mn |
| Sep 30, 2024 | -11.31 Mn |
| Jun 30, 2024 | -10.20 Mn |
| Mar 31, 2024 | -11.39 Mn |
| Dec 31, 2023 | -18.87 Mn |
| Sep 30, 2023 | -5.32 Mn |
| Jun 30, 2023 | -6.48 Mn |
| Mar 31, 2023 | -7.40 Mn |
| Dec 31, 2022 | 17.13 Mn |
| Sep 30, 2022 | -7.81 Mn |
| Jun 30, 2022 | -6.54 Mn |
| Mar 31, 2022 | -6.71 Mn |
| Dec 31, 2021 | -7.34 Mn |
| Sep 30, 2021 | -3.99 Mn |
| Jun 30, 2021 | -2.87 Mn |